Business Wire

NEXIGN

17.3.2021 09:02:14 CET | Business Wire | Press release

Share
Nexign and MegaFon Introduced the Unified Billing to Facilitate Digital Transformation

Nexign (a part of ICS Holding LLC), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, and MegaFon, the pan-Russian operator of digital opportunities, have completed the project of unifying billing systems for all 8 MegaFon’s subsidiaries on a single BSS platform. The companies also migrated subscriber data to the new environment with no impact on customers.

The need to go beyond classical telecom services pushed MegaFon to transform the billing core and develop a unified billing system in order to facilitate digital transformation. Among the strategic goals of the project were the reduction of total cost of ownership (TCO) by 20–30% and acceleration of new product launches.

In the course of the project, 7 billing systems utilized in MegaFon were replaced with a single solution. The process was seamless for customers, and the specifics and working arrangements of individual organizations was taken into account during the migration of the B2X segment.

MegaFon achieved the following results:

  • Unification of processes for all branch offices;
  • Transition from a regional-based to a single shared operation service, which resulted in the increase of its efficiency;
  • The product portfolio aligned within all branches of the operator while maintaining the flexibility of local pricing policy;
  • Introduction of joint call centers with the same service KPIs and standardized routes for handling calls;
  • Improved quality of customer service in the operator’s coverage area;
  • Time to market (TTM) for various product categoriesreduced by 2-5 times.

“The collaboration with Nexign has proven to be efficient and successful. We pursued a number of goals traditional for large companies. Aside from optimizing TCO and shortening the time to market for new services, we aimed to improve the customer experience and, as a result, facilitate digital and business transformation. We managed to move all 8 subsidiaries to unified billing processes and switch to a single operation service, which minimized support costs and enabled us to develop an ecosystem for the seamless integration of external partners,” says Sergey Nikiforets, Director of Digital Services at MegaFon PJSC .

Besides the actual implementation of the unified billing system, a number of related projects were completed:

  • The integration of the FastTrack methodology designed to automate the update implementation process. Consequently, the team responsible for it decided to spend no more than two weeks on minor changes to the system core — a process that used to last for about a year.
  • Development of a microservice factory . Its goal was to accelerate the formation of a partner ecosystem. By using this tool, MegaFon has already launched more than 100 new business projects.
  • The introduction of a product catalog that acts as a single point of development and modification of MegaFon’s products and services.

“The joint project with MegaFon is unique for the telecommunications market — both in terms of organized interaction and in terms of results achieved. The Nexign team carried out a comprehensive transformation of the operator’s systems, which enabled MegaFon to not only improve business efficiency and enter a new phase of development, but also to ensure customer loyalty while maintaining a high level of service in all regions. Whereas MegaFon will be able to upgrade the unified billing system to address short-term and long-term business challenges, Nexign’s scalable expertise will benefit telcos looking to develop digital services,” says Igor Gorkov, CEO of Nexign.

About Nexign

Nexign , a part of Intellectual Computer Systems Holding (ICS Holding) and a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, has been delivering value-driven, high-performance product solutions since 1992. Headquartered in St. Petersburg, Nexign employs more than 1,800 people. The company has offices and subsidiaries through Russia, the Commonwealth of Independent States, the Middle East, Africa and LATAM.

For more information, please visit the website and follow the latest news from Nexign on Twitter , Facebook and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye